Urinary Pigment Epithelium-Derived Factor as a Marker of Diabetic Nephropathy
Urinary Pigment Epithelium-Derived Factor as a Marker of Diabetic Nephropathy
复制标题
尿色素上皮衍生因子作为糖尿病肾病的标志物
DOI：
10.1159/000314326
复制
发表时间：
2010-01-01
影响因子：
4.2
通讯作者：
Jia, Weiping
中科院分区：
文献类型：
--
作者：
Chen, Haibing;Zheng, Zhi;Jia, Weiping
背景：色素上皮衍生因子（PEDF）是一种丝氨酸蛋白酶抑制剂，可调节肾脏细胞外基质的生成。我们寻找尿PEDF （uPEDF）与2型糖尿病（T2DM）患者肾病发展之间的关系。方法：采用ELISA法对2例人进行uPEDF测定。这些研究包括：(1)T2DM （n = 228）和健康对照（n = 49）的横断面研究；(2)高血压T2DM合并微量白蛋白尿（n = 42）的纵向研究，厄贝沙坦治疗6个月。在一项动物研究中，我们测量了对照大鼠、用链脲佐菌素治疗糖尿病的大鼠和用厄贝沙坦治疗3个月的糖尿病大鼠的肾脏和尿液样本中的PEDF。结果：横断面研究：与对照组相比，糖尿病肾病患者的uPEDF显著升高。uPEDF与MA独立相关。在MA组中，糖尿病视网膜病变患者的uPEDF显著高于非糖尿病视网膜病变患者。纵向研究：厄贝沙坦可显著降低T2DM合并MA患者的uPEDF。动物实验：在糖尿病大鼠的尿液和肾脏样本中都观察到PEDF的增加。uPEDF与肾脏PEDF表达有显著相关性。厄贝沙坦能显著降低糖尿病大鼠肾脏PEDF的表达和updf的表达。结论：uPEDF可作为T2DM患者肾病筛查和治疗反应监测的新标志物。版权所有：S. Karger AG，巴塞尔
Background: Pigment epithelium-derived factor (PEDF), a serine protease inhibitor, regulates extracellular matrix production in the kidney. We sought the association between urinary PEDF (uPEDF) and development of nephropathy among patients with type 2 diabetes (T2DM). Methods: Two human studies were performed in which uPEDF was determined by ELISA. These studies included (1) a cross-sectional study of T2DM (n = 228) and healthy controls (n = 49) and (2) a longitudinal study of hypertensive T2DM with microalbuminuria (MA; n = 42) treated with irbesartan for 6 months. An animal study was performed in which PEDF was measured in the kidney and urine samples of control rats, rats rendered diabetic with streptozotocin that were also fed a high-fat diet, and diabetic rats treated with irbesartan for 3 months. Results: Cross-sectional study: compared to controls, uPEDF was significantly higher in patients with diabetic nephropathy. uPEDF independently correlated with MA. In the MA group, uPEDF in patients with diabetic retinopathy was significantly higher than that in patients without diabetic retinopathy. Longitudinal study: irbesartan significantly decreased uPEDF in T2DM with MA. Animal study: in diabetic rats, increased PEDF was observed in both the urine and kidney samples. uPEDF showed a significant correlation with the expression of PEDF in the kidney. Irbesartan could significantly decrease the PEDF expression in the kidneys of diabetic rats as well as uPEDF. Conclusion: uPEDF may serve as a novel marker for screening for nephropathy among patients with T2DM and monitoring the response to therapy. Copyright (C) 2010 S. Karger AG, Basel